AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

The use of direct oral anticoagulants for stroke prevention in atrial fibrillation continues to
rise. Certain populations may be at higher risk for increased drug exposure and adverse …

Abstract Background Direct oral anticoagulants (DOACs) have emerged as safe and
effective alternatives to Vitamin-K antagonists for treatment and prevention of arterial and …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation
and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are …

Objectives During anticoagulant therapy, major bleeding is one of the most severe adverse
effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and …